Virpax Pharmaceuticals, a company specializing in developing product candidates for pain management, CNS and anti-viral indications, has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe.
The agreement with Seqens provides for both the supply material for Virpax’s clinical studies as well as the long-term commercial supply of MMS019. Seqens will conduct process development and validation of additional large scale commercial quantities of MMS019 at its facilities in Devens and Newburyport, MA.
“Establishing a collaboration with a strong partner capable of supplying clinical and commercial scale quantities of MMS019 is another important advancement in our MMS019 product development strategy. Seqens has a demonstrated expertise in developing and manufacturing highly-complex molecules for large scale production,” said Anthony Mack, chairman and CEO of Virpax. “Importantly, we expect this collaboration to support future development and supply additional molecular envelope technology programs under development, including Envelta and PES200, our post-traumatic stress disorder product candidate.”